Q1 FY 2027 saw 17% revenue growth and 72% EBITDA growth, with all segments contributing and margins expanding. CDMO and Complex Hospital Generics delivered strong results, supported by operational excellence, strategic investments, and robust order inflow.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.